INmune Bio, Inc. (NASDAQ:INMB) Receives Average Rating of "Hold" from Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been assigned an average recommendation of "Hold" from the eight brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $18.50.

Several research analysts recently issued reports on INMB shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of INmune Bio in a research report on Wednesday. Raymond James Financial downgraded shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a research report on Monday, June 30th. Scotiabank reiterated a "sector underperform" rating on shares of INmune Bio in a research report on Tuesday, July 1st. BTIG Research reiterated a "neutral" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Finally, Maxim Group reduced their price target on shares of INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, July 2nd.

INmune Bio Stock Performance

Shares of NASDAQ:INMB opened at $2.01 on Thursday. INmune Bio has a 52 week low of $1.71 and a 52 week high of $11.64. The company's fifty day moving average is $2.19 and its 200-day moving average is $4.85. The company has a market capitalization of $53.43 million, a PE ratio of -0.81 and a beta of 1.04.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.03. On average, analysts forecast that INmune Bio will post -2.24 EPS for the current year.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in INMB. Intech Investment Management LLC bought a new stake in INmune Bio during the 2nd quarter worth about $26,000. PFG Investments LLC bought a new stake in INmune Bio during the 2nd quarter worth about $27,000. Modera Wealth Management LLC bought a new stake in INmune Bio during the 2nd quarter worth about $36,000. Quarry LP bought a new stake in INmune Bio during the 1st quarter worth about $48,000. Finally, Oxford Asset Management LLP bought a new stake in INmune Bio during the 2nd quarter worth about $52,000. 12.72% of the stock is owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.